Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key...

Today, Alvotech filed with the U.S. Securities and Exchange Commission (SEC) a request for withdrawal of a registration statement on form F-1. This request is related to to a registration statement which was originally filed with the SEC in July 2022, to register for resale up to 15.3 million shares

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of...

Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in EuropeAdvanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure...

On June 14, 2024, Alvotech filed information on Form 6-K with the U.S. Securities and Exchange Commission, pertaining to an Open Market Sale Agreement with Jefferies LLC, an accompanying Prospectus Supplement and legal opinion from Arendt & Medernach SA relating to the validity of the securities to

STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central...